Journal: Veterinary Medicine International

Article Title: In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide

doi: 10.4061/2010/891010

Figure Lengend Snippet: Effect of NTZ (closed) or TIZ (open) against CIV (Ca/CO-1 (▲, Δ) Ca/CO-3 (■, □) and Ca/CO-4 (♦, ◊ )) relative to the replication of the untreated controls in MDCK cells.

Article Snippet: Nitazoxanide (NTZ) was provided by IDEXX Laboratories (Westbrook, ME, USA) and tizoxanide (TIZ) was provided by Romark Laboratories (Tampa, FL, USA).

Techniques:

Journal: Veterinary Medicine International

Article Title: In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide

doi: 10.4061/2010/891010

Figure Lengend Snippet: In vitro activity of nitazoxanide (NTZ) and its active metabolite tizoxanide (TIZ) on clinical isolates of canine influenza virus (CIV).

Article Snippet: Nitazoxanide (NTZ) was provided by IDEXX Laboratories (Westbrook, ME, USA) and tizoxanide (TIZ) was provided by Romark Laboratories (Tampa, FL, USA).

Techniques: In Vitro, Activity Assay, Virus

Journal: Pathogens

Article Title: Drug Sensitivity of Vaccine-Derived Rubella Viruses and Quasispecies Evolution in Granulomatous Lesions of Two Ataxia-Telangiectasia Patients Treated with Nitazoxanide

doi: 10.3390/pathogens11030338

Figure Lengend Snippet: Inhibition of replication of iVDRV strains isolated from skin lesions before and after the NTZ therapies. ( A ). Dose response analysis of A549 cells treated with tizoxanide and infected with iVDRV strains. Data represent the mean of three (RA27/3, CA strains) or four (RI strains) independent experiments +/− SD. ( B ). Table of IC 50 and IC 90 of tizoxanide in A459 cells infected with iVDRV strains.

Article Snippet: A549 cells plated in 96-well plates at a density of 2 × 10 4 per well were infected at an MOI of 0.1 with RuV strains and then treated with tizoxanide (Cayman Chemical Company, Ann Arbor, MI, USA) at various concentrations.

Techniques: Inhibition, Isolation, Infection

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials

doi: 10.1128/AAC.00222-20

Figure Lengend Snippet: Structure-activity relationship (SAR) analysis of tizoxanide derivatives. Structures of tizoxanide and its derivatives are shown for compounds 1a to 4d. The EC50 values were defined as the concentration of inhibitor required to reduce 50% CPE in the infectivity assay. Values were determined by nonlinear regression and are presented as means ± standard deviations from three independent experiments. SAR was summarized according to the experimental inhibition data (EC50).

Article Snippet: Tizoxanide was purchased from Key Organics, Ltd. (Cornwall, UK).

Techniques: Activity Assay, Concentration Assay, Infection, Inhibition

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials

doi: 10.1128/AAC.00222-20

Figure Lengend Snippet: Activity of the compounds 4a/4d against multiple influenza virus strains

Article Snippet: Tizoxanide was purchased from Key Organics, Ltd. (Cornwall, UK).

Techniques: Activity Assay, Virus

Journal: medRxiv

Article Title: Atazanavir/ritonavir increased tizoxanide exposure from oral nitazoxanide through pharmacokinetic interaction in healthy volunteers

doi: 10.1101/2023.09.20.23295544

Figure Lengend Snippet: Plasma concentration-time curve of tizoxanide alone and with atazanavir/ritonavir (ATZ/r); data is presented here as mean (95% CI) for n =18

Article Snippet: All working stock solutions and plasma working stock were prepared from a 1 mg/mL stock solution prepared from tizoxanide reference compound (Toronto Research Chemicals Inc., Toronto, ON, Canada).

Techniques: Clinical Proteomics, Concentration Assay

Journal: medRxiv

Article Title: Atazanavir/ritonavir increased tizoxanide exposure from oral nitazoxanide through pharmacokinetic interaction in healthy volunteers

doi: 10.1101/2023.09.20.23295544

Figure Lengend Snippet: Linearity between tizoxanide plasma concentrations DBS concentrations

Article Snippet: All working stock solutions and plasma working stock were prepared from a 1 mg/mL stock solution prepared from tizoxanide reference compound (Toronto Research Chemicals Inc., Toronto, ON, Canada).

Techniques: Clinical Proteomics

Journal: medRxiv

Article Title: Atazanavir/ritonavir increased tizoxanide exposure from oral nitazoxanide through pharmacokinetic interaction in healthy volunteers

doi: 10.1101/2023.09.20.23295544

Figure Lengend Snippet: Linearity between tizoxanide plasma concentrations DBS concentrations (broken line represents true line of identity)

Article Snippet: All working stock solutions and plasma working stock were prepared from a 1 mg/mL stock solution prepared from tizoxanide reference compound (Toronto Research Chemicals Inc., Toronto, ON, Canada).

Techniques: Clinical Proteomics

Journal: bioRxiv

Article Title: Optimisation and validation of a sensitive bioanalytical method for niclosamide

doi: 10.1101/2021.01.13.426426

Figure Lengend Snippet: shows representative chromatograms from the high dynamic range method for the blank plasma (A), lower limit of quantification (31.25ng/mL) (B) and the highest standard (2000ng/mL) (C). Representative chromatograms for the low dynamic range method are shown for the blank plasma (D), lower limit of quantification (0.78ng/mL) (E) and the highest standard (100ng/mL) (F). The peak produced by niclosamide had a retention time of 2.5 minutes and the peak produced by the IS tizoxanide had a retention time 2.09 minutes.

Article Snippet: Niclosamide and the internal standard (IS) tizoxanide were purchased from Stratech Scientific Ltd (Cambridge, UK).

Techniques: Produced